scholarly journals RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM

2019 ◽  
pp. 36-43
Author(s):  
E. A. Shcheglov ◽  
N. N. Alontseva ◽  
P. S. Guliaeva
Keyword(s):  
Deep Vein Thrombosis ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Therapeutic Option ◽  
Anticoagulant Treatment ◽  
Vein Thrombosis ◽  
Duodenal Bleeding ◽  
Ulcerative Lesions ◽  
Time Of Admission ◽  
Deep Vein

The aim of this study was to assess the risk of use of rivaroxaban, which was associated with gastro-duodenal bleeding in patients with deep venous thrombosis. Methods: an analysis of anticoagulant treatment in 683 patients with deep venous phlebothrombosis. All the patients underwent fiberoptic gastroduodenoscopic procedure prior to the anticoagulant treatment. When erosive-ulcerative lesions were detected, the patients received antisecretory therapy with proton pump inhibitors along with anticoagulant therapy. Results: EGD did not show any only stomach pathology only in 10.7 percent of patients at the time of admission. A symptom-free pathology that became a diagnostic finding was identified in 53.1 percent of patients. Fiberoptic gastroduodenoscopy showed completed bleeding or bleeding that was stopped using endoscopic balloon tamponade with achievement of stable hemostasis in 12.9 patients. 59.1 percent of patients received anti-coagulant therapy with rivaroxaban (Xarelto®). In the presented series of patients with acute deep vein thrombosis, the use of rivopoxaban appeared a safe therapeutic option not only in patients with erosive-ulcerative lesions in the gastroduodenal system, but also in those with endoscopic signs of stopped bleeding (on the top of already administered antisecretory therapy with proton pump inhibitors).

Predictive Value of Decreasing Antithrombin III in Deep-Vein Thrombosis

1980 ◽  
Vol 44 (03) ◽  
pp. 135-137 ◽  
Author(s):  
Thorkild Lund Andreasen
Keyword(s):  
Deep Vein Thrombosis ◽  
Predictive Value ◽  
Coronary Care Unit ◽  
Antithrombin Iii ◽  
Predictive Values ◽  
Vein Thrombosis ◽  
At Iii ◽  
Coronary Care ◽  
Time Of Admission ◽  
Deep Vein

SummaryAntithrombin III (At-III) was measured at the time of admission and two days later in 131 patients laid up in a coronary care unit. The patients were examined for deep-vein thrombosis (DVT) clinically and by means of 125I-fibrinogen scanning. 19 patients developed DVT. In 11 subjects with and 25 without DVT At-III decreased more than 10%. And in 7 with and 17 without DVT At-III decreased more than 15%. One person with DVT had subnormal At-III. By using decrease of At-III or subnormal initial At-III to predict DVT the following predictive value (PV) were found. Decrease ≤ 10%, PV pos.= 0.32 and PV neg. = 0.93. Decrease ≤ 15%, PV pos. = 0.32 and PV neg. = 0.90. The positive predictive values obtained were too low to let decreasing At-III give occasion for prophylactic anticoagulant treatment.

IMPACT OF TIME OF ADMISSION ON DEEP VEIN THROMBOSIS DVT PROPHYLAXIS IN A CLOSED MEDICAL INTENSIVE CARE UNIT

CHEST Journal ◽  
2007 ◽  
Vol 132 (4) ◽  
pp. 625C
Author(s):  
Hani Jaouni ◽  
Shadi Haddadin ◽  
Lenora Adams ◽  
Joshua S. Botdorf ◽  
Maen B. Nusair ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Deep Vein Thrombosis ◽  
Medical Intensive Care Unit ◽  
Vein Thrombosis ◽  
Dvt Prophylaxis ◽  
Medical Intensive Care ◽  
Time Of Admission ◽  
Deep Vein

Anemia with Proton-Pump Inhibitor;Psoriasis Flare-Ups with Selective Serotonin Reuptake Inhibitor;Exacerbation of Tuberculosis Due to Infliximab Therapy;Hepatitis Seen with Celecoxib;Thalidomide-Associated Deep Vein Thrombosis and Pulmonary Embolism;Chronic ADRs Associated with Hepatitis B Vaccination;Neurologic Disorders with MMR Vaccines?

2003 ◽  
Vol 38 (2) ◽  
pp. 112-128
Author(s):  
Joel Shuster
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Proton Pump Inhibitor ◽  
Hepatitis B ◽  
Proton Pump ◽  
Hepatitis B Vaccination ◽  
Drug Reactions ◽  
Vein Thrombosis ◽  
Neurologic Disorders ◽  
Deep Vein

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

scholarly journals https://www.cardiologiaambulatoriale.eu/osimertinib-induced-venous-thromboembolism-in-lung-cancer-a-challenging-clinical-case/

2020 ◽  
pp. 276-280
Author(s):  
Tiziana Leopizzi ◽  
Agnese Maria Fioretti
Keyword(s):  
Lung Cancer ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Therapeutic Option ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
T790m Mutation ◽  
Vein Thrombosis ◽  
Deep Vein

Venous thromboembolism is the second leading cause of mortality among cancer patients, with a 20% incidence, after the progression of cancer itself. In the last two years clinical trials have studied direct oral anticoagulants also in the oncological clinical setting with prom-ising results in efficacy and safety. Osimertinib has been approved for the treatment of EGFR T790M mutation-positive non small cell lung cancer resistant to first- and second-generation EGFR tirosin kinase inhibitors. However, little is known about venous thromboem-bolism induced by osimertinib. Here, we report the case of a woman with lung cancer treated by osimertinib who developed deep vein thrombosis of the common femoral right vein, successfully treated wih edoxaban. In conclusion, on one side deep vein thrombosis is a possible side effect of osimertinib, on the other side edoxaban is a new practical, effective and safe therapeutic option also in active cancer patients.

Correction: long-term anticoagulant therapy (6 May 1983; 22: 33)

1984 ◽  
Vol 22 (3) ◽  
pp. 12.2-12
Keyword(s):  
Deep Vein Thrombosis ◽  
Anticoagulant Therapy ◽  
Anticoagulant Treatment ◽  
Single Episode ◽  
Vein Thrombosis ◽  
Deep Vein

The article suggested that after a single episode of deep-vein thrombosis anticoagulant treatment should if possible be continued for at least 6 months. After reconsidering the evidence we think a shorter period, for 3 to 4 months, is more appropriate.

Effect of anticoagulant treatment in deep vein thrombosis: A patient-specific computational fluid dynamics study

2015 ◽  
Vol 48 (10) ◽  
pp. 2047-2053 ◽  
Author(s):  
Gerard Fortuny ◽  
Joan Herrero ◽  
Dolors Puigjaner ◽  
Carme Olivé ◽  
Francesc Marimon ◽  
...  
Keyword(s):  
Fluid Dynamics ◽  
Computational Fluid Dynamics ◽  
Deep Vein Thrombosis ◽  
Patient Specific ◽  
Anticoagulant Treatment ◽  
Vein Thrombosis ◽  
Deep Vein
Sign in / Sign up

Export Citation Format

Share Document